Novo shares slide as drugmaker lays out post-Wegovy growth strategy
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
ImpactNotable 30/100
Why it mattersRule-based estimate: no strong signals; trust 7/10.
RegionsGlobal
Published3 h ago (Mon, 21 Sep 2026 10:40:51 GMT)
RetrievedMon, 21 Sep 2026 12:01:06 GMT via rss
ClassifiedMon, 21 Sep 2026 12:01:12 GMT by heuristic